Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Vaxxinity Starts Dosing In Phase 1 Migraine Vaccine Trial

Vaxxinity Inc (NASDAQ:VAXX) announced that the first subjects had been dosed in the Phase 1 clinical trial of UB-313, a vaccine…
byVandana Singh
September 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Vaxxinity Inc (NASDAQ:VAXX) announced that the first subjects had been dosed in the Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine.
  • The Phase 1 randomized, placebo-controlled, double-blind, multidose trial will enroll approximately 40 healthy volunteers in Belgium. 
  • The trial’s objectives are to evaluate safety, tolerability, and immunogenicity. Serum anti-CGRP antibody titers will measure immunogenicity. Pharmacodynamics of the immune response will be measured by the inhibition of the capsaicin-induced increase in dermal blood flow, an established model of target engagement in migraine.
  • Price Action: VAXX shares are trading 2.09% higher at $2.20 on the last check Tuesday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What’s Going On With EV-Maker Nikola’s Stock?

By Erica Kollmann
April 5, 11:06 AM
Nikola produced 43 and wholesaled 40 Class 8 Nikola hydrogen fuel cell EVs in the first quarter of 2024 and announced it has begun to return its battery-electric trucks (BEV) associated with a voluntary recall last year. Nikola announced on Friday it will report its first-quarter financial results on May 7 and host a conference call to discuss the results at 10:30 a.m. ET the same day. According to estimates from Benzinga Pro, the company is expected to report losses of 10 cents per share and quarterly revenue of $14.235 million. 

NKLA